Aim: Prospective studies support the clinical impact of pharmacogenomics (PGx)-guided
prescribing to reduce severe and potentially fatal adverse effects. Drug-gene interactions …

Treatment response variability across patients is a common phenomenon in clinical practice.
For many drugs this inter-individual variability does not require much (if any) …

Objectives Pharmacogenetic panel-based testing represents a new model for precision
medicine. A sufficiently powered prospective study assessing the (cost-) effectiveness of a …

Comparative effectiveness research (CER) in genomic medicine (GM) measures the clinical
utility of using genomic information to guide clinical care in comparison to appropriate …

Pharmacogenomics (PGx), a substantial component of “personalized medicine”, seeks to
understand each individual's genetic composition to optimize drug therapy––maximizing …

In recent years, substantial effort has been made to better understand the influence of
genetic factors on the efficacy and safety of numerous medications. These investigations …

The vitamin K antagonist is a commonly prescribed effective oral anticoagulant with a
narrow therapeutic range, and the dose requirements for different patients varied greatly. In …

Although the clinical validity of a number of pharmacogenetic markers is nowadays a matter
of fact, and led authoritative scientific consortia as the Dutch Pharmacogenetic Working …

Objectives International guidelines recommend that an average individual time in
therapeutic range should be> 65% to 70% for optimal efficacy and safety outcomes while …

Warfarin (brand name Coumadin) is an anticoagulant (blood thinner). Warfarin acts by
inhibiting the synthesis of vitamin K-dependent clotting factors and is used in the prevention …